Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Injectable Peptide-Based Biomaterials for Stem Cell and Therapeutics Delivery for Soft Tissue and Organ Treatment

EF 2023-24

Résumé
The cornea is the outermost structure of the eye responsible for two-thirds of the eye’s focusing power and is important for vision. Corneal blindness ranks 4th among global causes of vision loss. Keratoconus (KC), a corneal disease, involves collagen loss in the thickest layer of the cornea. This results in gradual corneal thinning leading to a cone-shaped bulge, and eventual vision loss. Currently, mid-stages of KC are managed by collagen crosslinking to stabilize the remaining collagen in the cornea and slow further thinning. Therefore, it is only a temporary solution as it does not regenerate the lost collagen. For late stages, corneal transplantation is required but cornea shortages prevent 53% of patients around the world from getting one. Injectable peptide biomaterials are promising in repairing tissues and organs, but they use animal collagen which is expensive and problematic for human clinical use. In this study, we develop chemical-free biomaterials, containing lab-made collagen-like peptides to create injectable hydrogels. These hydrogels aim to both thicken the cornea and help deliver stem cells and therapeutic molecules. We previously developed biomaterials to thicken corneas affected by KC and reshape their curvature. Here, our aim is to reformulate the biomaterials to add small peptide units (motifs), increase their pore sizes to allow cells to receive nutrients and oxygen, and control their biodegradability. This improves biocompatibility with stem cells/therapeutics and facilitate their release. We then package stem cells/therapeutic molecules in the biomaterials and test them on a KC model in pig eyes. This approach not only replaces lost collagen in KC-affected corneas but also presents a cellular regenerative strategy for collagen-producing cells.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506015
Name
EL-Hage Jinane
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Injectable Peptide-Based Biomaterials for Stem Cell and Therapeutics Delivery for Soft Tissue and Organ Treatment
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Delivery; Collagen; Cornea; Drug Delivery; Inflammation; Injectable Biomaterials; Keratoconus; Peptide Biomaterials; Stem Cells; Vision
Abstract
The cornea is the outermost structure of the eye responsible for two-thirds of the eye’s focusing power and is important for vision. Corneal blindness ranks 4th among global causes of vision loss. Keratoconus (KC), a corneal disease, involves collagen loss in the thickest layer of the cornea. This results in gradual corneal thinning leading to a cone-shaped bulge, and eventual vision loss. Currently, mid-stages of KC are managed by collagen crosslinking to stabilize the remaining collagen in the cornea and slow further thinning. Therefore, it is only a temporary solution as it does not regenerate the lost collagen. For late stages, corneal transplantation is required but cornea shortages prevent 53% of patients around the world from getting one. Injectable peptide biomaterials are promising in repairing tissues and organs, but they use animal collagen which is expensive and problematic for human clinical use. In this study, we develop chemical-free biomaterials, containing lab-made collagen-like peptides to create injectable hydrogels. These hydrogels aim to both thicken the cornea and help deliver stem cells and therapeutic molecules. We previously developed biomaterials to thicken corneas affected by KC and reshape their curvature. Here, our aim is to reformulate the biomaterials to add small peptide units (motifs), increase their pore sizes to allow cells to receive nutrients and oxygen, and control their biodegradability. This improves biocompatibility with stem cells/therapeutics and facilitate their release. We then package stem cells/therapeutic molecules in the biomaterials and test them on a KC model in pig eyes. This approach not only replaces lost collagen in KC-affected corneas but also presents a cellular regenerative strategy for collagen-producing cells.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
EL-Hage, Jinane
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~